Physician profile
Daniel B Friedman
NPI 1992899363
$6,260.18
in general payments reported to CMS, 2019-2025
23 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $294 · 2021: $464 · 2022: $634 · 2023: $696 · 2024: $2,949 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121 · Travel and Lodging: $1,021 · Education: $50.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.79 |
| Travel and Lodging | $1,020.89 |
| Education | $50.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,692.67 | 2023-2024 | Linq II |
| Novartis Pharmaceuticals Corporation | $676.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $638.19 | 2019-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $574.33 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $405.49 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.90 | 2020-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $292.10 | 2021-2024 | Xarelto |
| Janssen Scientific Affairs, LLC | $283.10 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $261.48 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $209.86 | 2021-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $163.27 | 2019-2023 | Watchman Access System |
| Heartflow, INC. | $161.51 | 2025 | |
| Amgen INC. | $153.18 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.55 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $80.74 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $42.67 | 2019-2020 | |
| Astellas Pharma US INC | $36.22 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $29.31 | 2022 | |
| Inari Medical, INC. | $29.27 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $23.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.32 | 2025 | |
| Atricure, INC. | $18.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.